NCT01232881终止不适用
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study
Hoosier Cancer Research Network1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2009年8月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- To correlate tumor gene expression (genomic profile) with response to lonafarnib in patients with advanced breast cancer
研究概览
简要总结
This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
详细描述
OUTLINE: This is a multi-center study.
Sample Collection:
- Tumor sample
- Serum sample
Treatment Regimen:
- All registered patients must be planning treatment with lonafarnib
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
- •Age > 18 years.
- •Planned treatment with lonafarnib for metastatic breast cancer.
- •Must consent to have a biopsy performed to obtain fresh tissue or be able to identify a formalin fixed paraffin embedded (FFPE) tissue block in which tumor samples can be obtained to complete the testing for this study.
排除标准
- •Planned treatment with any other treatment regimen
结局指标
主要结局
To correlate tumor gene expression (genomic profile) with response to lonafarnib in patients with advanced breast cancer
时间窗: 24 months
次要结局
- To correlate serum and tumor proteomic profiles with response to lonafarnib(24 months)
- To compare serum and tissue proteomic analyses(24 months)
- To compare genomic and proteomic profiles(24 months)
- To correlate toxicity and /or response with drug-specific pharmacogenomic parameters(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Understanding and Predicting Breast Cancer Events After TreatmentBreast CancerNCT02791581Wake Forest University Health Sciences403
进行中（未招募）
不适用
Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or LeukemiaBreast CancerLymphomaLeukemiaNCT04541212Montreal Heart Institute169
已完成
不适用
Assessing Treatment Response in Breast Cancer With Functional ImagingBreast CancerNCT02688257Institute of Cancer Research, United Kingdom53
招募中
不适用
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity TestingCancer of the BreastBreast CancerNCT04968964Washington University School of Medicine55
招募中
不适用
Serum and Tissue Metabolite-based Prediction of Sentinel Lymph Node Metastasis in Breast CancerLymph Node MetastasisBreast CancerNCT06001528Shantou Central Hospital2,400